News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lyss_Alan_MO_new_web.jpg)
New targeted treatments are major advances for HER2-positive breast cancer
- Author:
- Alan P. Lyss, MD
Dr. Alan Lyss reviews data on HER2-targeted therapies in breast cancer.
Article
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
The power and promise of social media in oncology
- Author:
- Alan P. Lyss, MD
Dr. Alan Lyss describes a recent presentation on the role of social media in oncology.
Article
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
IMvigor130: A treasure trove of data for urothelial carcinoma
- Author:
- Alan P. Lyss, MD
Dr. Alan Lyss reviews updated results with atezolizumab in locally advanced or metastatic urothelial carcinoma.
Article
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lyss_Alan_MO_new_web.jpg)
Leveraging the microbiome to enhance cancer treatment
- Author:
- Alan P. Lyss, MD
Dr. Alan Lyss reviews research suggesting that an antibiotic can improve the efficacy of radiotherapy.
Article
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lyss_Alan_MO_new_web.jpg)
Steroid-refractory pneumonitis from ICIs: Experience at major centers
- Author:
- Alan P. Lyss, MD
Dr. Alan Lyss explores two studies of patients with steroid-resistant or refractory pneumonitis resulting from...
Article
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lyss_Alan_MO_new_web.jpg)
mCODE: Improving data sharing to enhance cancer care
- Author:
- Alan P. Lyss, MD
Dr. Alan Lyss explores mCODE, a project designed to improve the sharing of data from cancer patients.
Article
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lyss_Alan_MO_new_web.jpg)
Genetic testing for breast and ovarian cancer: What has changed and what still needs to change?
- Author:
- Alan P. Lyss, MD
Dr. Alan Lyss reviews a study that revealed trends in genetic testing over time.
Opinion
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lyss_Alan_MO_new_web.jpg)
Enfortumab vedotin offers hope to poor-prognosis patients with advanced urothelial cancer
- Author:
- Alan P. Lyss, MD
EV is an antibody-drug conjugate directed against nectin-4, an immunoglobulin-like cell adhesion molecule that...
Article
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lyss_Alan_MO_new_web.jpg)
How has the pandemic affected rural and urban cancer patients?
- Author:
- Alan P. Lyss, MD
A survey suggests the pandemic has impacted rural and urban cancer patients somewhat differently.
Article
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lyss_Alan_MO_new_web.jpg)
X-ray vision: Using AI to maximize the value of radiographic images
- Author:
- Alan P. Lyss, MD
Dr. Alan Lyss reviews studies using artificial intelligence to predict lung cancer risk and outcomes.
Article
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lyss_Alan_MO_new_web.jpg)
ctDNA outperforms CEA in colorectal cancer
- Author:
- Alan P. Lyss, MD
Circulating tumor DNA testing bested carcinoembryonic antigen testing in a study of patients with colorectal...
Article
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lyss_Alan_MO_new_web.jpg)
RSClin: A new tool for ‘TAILOR-ing’ treatment in early breast cancer
- Author:
- Alan P. Lyss, MD
Dr. Alan P. Lyss describes RSClin, a tool for estimating the risk of distant relapse in breast cancer. ...
Article
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lyss_Alan_MO_new_web.jpg)
DART trial hits the target in angiosarcoma
- Author:
- Alan P. Lyss, MD
Dr. Alan Lyss reviews results of the DART trial and highlights the value of clinical trials for rare cancers....
Article
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lyss_Alan_MO_new_web.jpg)
How should we evaluate the benefit of immunotherapy combinations?
- Author:
- Alan P. Lyss, MD
Dr. Alan Lyss examines how new endpoints, novel study design, and other methods might better quantify the...
Article
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Lyss_Alan_MO_new_web.jpg)
Using telehealth to deliver palliative care to cancer patients
- Author:
- Alan P. Lyss, MD
Dr. Alan Lyss discusses the use of telehealth for palliative cancer care, including results from the REACH PC trial.